Fortress Biotech, Inc.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
▼ -95.3% over 5Y.
today you would have $47.20▼ -95.3%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 15 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $3.66 | $2.03 | $3.01 | $9.90 | $37.50 | $47.55 | $38.55 | $12.90 | $59.85 | $40.50 | $41.85 | $36.60 | $39.45 | $67.65 | $97.50 | |
| P/S | 2.0x | 1.8x |
Seven formulas applied to what the company reported. None of them predicts a price — each answers what the stock would be worth if its assumption held. The assumption is printed next to every number, because it is the assumption that produces the result.
Square root of 22.5 × earnings × book value — the two ceilings Graham proposed. Blind to intangibles, so it undervalues software and brands.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| ACRVAcrivon Therapeutics, Inc. | $2.15 | — | 1.1x | — | -64.63% | $92.13M |
| ACHAccendra Health Inc | $1.21 | — | — | — | — | $93.05M |
| ICCCImmucell Corp | $9.94 | 142.0x | 2.9x | — | 2.57% | $90.28M |
| PTHSPelthos Therapeutics Inc. | $24.73 |
Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally. The company offers Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for the treatment of axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne; Amzeeq, a minocycline topical foam for the treatment of lesions of non-nodular moderate to severe acne vulgaris; Zilxi, a minocycline topical foam for the treatment of lesions of rosacea; Exelderm, an antifungal cream for topical use; Targadox, an oral doxycycline drug for the therapy of severe acne; Luxamend, a water-based emulsion for the treatment of superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, first and second-degree burns, and radiation dermatitis; and UNLOXCYT, a death-ligand 1 blocking antibody for the treatment of metastatic cutaneous squamous cell carcinoma. It also develops CUTX-101, a copper histidinate injection, which is in FDA approved stage for the treatment of Menkes disease; IV Tramadol, an intravenous formulation, which is in NDA/BLA filed stage for the treatment of post-operative acute pain; Dotinurad, a urate transporter inhibitor, which is in Phase III for the treatment of gout and chronic kidney diseases; CAEL-101, a light chain fibril-reactive monoclonal antibody, which is in Phase III for the treatment of amyloid light chain amyloidosis; and Triplex, a universal recombinant modified vaccinia ankara viral vector vaccine, which is in Phase II for the treatment of cytomegalovirus, anti-human immunodeficiency virus, non-hodgkin lymphoma, and acute lymphoblastic leukemia. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.
Company description provided by Yahoo Finance.
| 1.0x |
| 0.5x |
| 1.0x |
| 3.7x |
| 6.6x |
| 5.5x |
| 2.0x |
| 1.1x |
| 8.2x |
| 156.9x |
| — |
| — |
| — |
| — |
| P/B | 2.5x | 2.3x | 2.5x | 2.0x | 1.7x | 2.3x | 3.0x | 7.7x | 28.5x | 3.9x | 3.5x | 2.4x | 1.6x | 1.4x | 5.3x | 6.3x |
| EPS | -$0.07 | -$2.69 | -$8.47 | -$15.97 | -$11.85 | -$9.75 | -$10.95 | -$29.10 | -$24.15 | -$20.70 | -$18.60 | -$8.40 | -$18.30 | -$19.05 | -$82.65 |
| Profit margin | -102.03% | 10.77% | -79.75% | -71.75% | -114.30% | -94.06% | -102.03% | -109.09% | -313.02% | -35.65% | -334.31% | -5611.59% | — | — | — | — |
| ROE | -127.21% | 13.66% | -202.30% | -268.97% | -207.51% | -59.54% | -46.37% | -152.43% | -4543.57% | -127.21% | -143.12% | -85.19% | -28.91% | -45.72% | -125.31% | -190.05% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Not the average of the seven numbers above. Four of the seven start from the same earnings per share — Graham, Lynch, sector multiples and its own history — so averaging all seven would let one input count four times and drown out the others. Instead each family produces one number, and the fair price is the average of the families that answered. A family with two working formulas contributes their average, not two votes.
1 methods answered, across 1 families.
Every formula reads the same reported statements and they can be wrong together. The margin is room for that.
+532.6% from the average.
These are models, not forecasts, and not investment advice. Change one assumption and the number changes with it — that is a property of valuation, not a defect of this page.
| — |
| — |
| — |
| — |
| $94.68M |
| DWTXDogwood Therapeutics, Inc. | $2.65 | 1.2x | 1.3x | — | -47.77% | $90.08M |
| DHDefinitive Healthcare Corp. | $0.89 | — | 0.7x | — | -78.37% | $95M |